Machina Capital S.A.S. Cuts Stock Holdings in Chemed Corporation $CHE

Machina Capital S.A.S. trimmed its position in shares of Chemed Corporation (NYSE:CHE) by 22.8% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 478 shares of the company’s stock after selling 141 shares during the quarter. Machina Capital S.A.S.’s holdings in Chemed were worth $233,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. Kayne Anderson Rudnick Investment Management LLC lifted its position in shares of Chemed by 2.6% during the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 597,175 shares of the company’s stock valued at $367,454,000 after buying an additional 15,041 shares during the last quarter. Neuberger Berman Group LLC grew its position in Chemed by 3.9% during the 1st quarter. Neuberger Berman Group LLC now owns 521,212 shares of the company’s stock worth $320,712,000 after purchasing an additional 19,650 shares during the last quarter. Boston Trust Walden Corp grew its position in Chemed by 0.4% during the 2nd quarter. Boston Trust Walden Corp now owns 247,434 shares of the company’s stock worth $120,483,000 after purchasing an additional 1,083 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Chemed by 9.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 218,675 shares of the company’s stock worth $134,547,000 after purchasing an additional 19,421 shares during the last quarter. Finally, Northern Trust Corp grew its position in Chemed by 3.4% during the 1st quarter. Northern Trust Corp now owns 215,523 shares of the company’s stock worth $132,616,000 after purchasing an additional 6,988 shares during the last quarter. 95.85% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on CHE. Bank of America dropped their target price on shares of Chemed from $610.00 to $595.00 and set a “buy” rating on the stock in a research report on Wednesday, September 10th. Oppenheimer dropped their target price on shares of Chemed from $650.00 to $580.00 and set an “outperform” rating on the stock in a research report on Thursday, July 31st. Zacks Research raised shares of Chemed from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 30th. Royal Bank Of Canada reduced their price target on shares of Chemed from $640.00 to $589.00 and set an “outperform” rating for the company in a research report on Thursday, July 31st. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Chemed in a research report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $578.50.

Chemed Price Performance

CHE opened at $438.94 on Wednesday. The firm has a fifty day moving average price of $447.22 and a 200 day moving average price of $490.18. Chemed Corporation has a 1 year low of $408.42 and a 1 year high of $623.60. The stock has a market cap of $6.40 billion, a P/E ratio of 23.21, a P/E/G ratio of 2.69 and a beta of 0.43.

Chemed (NYSE:CHE) last posted its earnings results on Tuesday, October 28th. The company reported $5.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.39 by ($0.12). Chemed had a net margin of 11.02% and a return on equity of 25.89%. The firm had revenue of $624.90 million during the quarter, compared to analyst estimates of $626.04 million. During the same quarter in the prior year, the firm earned $5.64 earnings per share. The business’s revenue for the quarter was up 3.1% on a year-over-year basis. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. Equities analysts expect that Chemed Corporation will post 21.43 EPS for the current year.

Insider Buying and Selling at Chemed

In related news, CEO Kevin J. Mcnamara sold 3,000 shares of the business’s stock in a transaction on Friday, September 26th. The shares were sold at an average price of $461.28, for a total value of $1,383,840.00. Following the completion of the sale, the chief executive officer owned 96,197 shares of the company’s stock, valued at approximately $44,373,752.16. The trade was a 3.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Patrick P. Grace sold 150 shares of the business’s stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $463.39, for a total transaction of $69,508.50. Following the completion of the sale, the director directly owned 3,397 shares of the company’s stock, valued at approximately $1,574,135.83. The trade was a 4.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 3.29% of the company’s stock.

Chemed Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.